FDA’s Testosterone Flip: Heart Scare Gone, New Risk Lands

The Food and Drug Administration just admitted testosterone is not the heart-attack time bomb critics claimed, but it quietly replaced one warning with another that may matter even more for you.

Story Snapshot

The Food and Drug Administration removed its major heart-risk warning from testosterone labels but kept strict limits on who should use it.
New science from the TRAVERSE trial shows no extra heart attacks or strokes in properly treated men, yet blood pressure does rise on therapy.
The Food and Drug Administration now forces every testosterone product to warn about increased blood pressure and to share detailed trial data.
For middle-aged men, this shift signals conditional approval, not a free pass: benefits are real, but so are blood-pressure and clotting concerns.

The old scare story just broke, but the fine print got sharper

For a decade, many doctors treated testosterone therapy like playing roulette with your heart. That fear came from early studies and a 2015 Food and Drug Administration move that slapped warnings about possible extra heart attacks and strokes on every testosterone label. Those warnings chilled treatment for men with real hormone deficiency, even when they were exhausted, depressed, and losing muscle. The new 2025 change is the first official signal that the science has moved on.

The turning point was a large clinical trial called TRAVERSE. It followed about 5,200 men with confirmed low testosterone and high cardiovascular risk, comparing testosterone versus placebo for almost three years. The trial showed no extra risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in the testosterone group. That result is why the Food and Drug Administration ordered the cardiovascular risk language pulled from the boxed warning on all testosterone products.

Why your blood pressure just became the headline risk

While TRAVERSE calmed the heart-attack panic, other required studies raised a different red flag. The Food and Drug Administration forced companies to run ambulatory blood pressure monitoring, which tracks real-world blood pressure changes after starting testosterone. Those studies confirmed a class-wide rise in blood pressure across testosterone products. The increase is modest on average, but even a few points matter when millions of men already stand on the edge of hypertension and stroke risk.

Because of that, the same announcement that removed the heart-risk language also added new, stronger blood-pressure warnings. Every testosterone product must now either list its own detailed blood-pressure data, if available, or carry a clear general warning about increased blood pressure until those studies are done. This is the right trade: do not scare men with risks that large trials failed to confirm, but do not hide a risk that shows up across products and could push borderline patients into serious trouble.

Who the Food and Drug Administration still says testosterone is for

Even as it softened the cardiovascular warning, the Food and Drug Administration refused to loosen who officially qualifies. Labels still limit testosterone therapy to men with primary or hypogonadotropic hypogonadism, meaning clear medical causes like testicular damage or pituitary disease, confirmed by blood tests and symptoms. The agency kept the “Limitation of Use” language that says age-related low testosterone remains off-label, with safety and effectiveness not established for that group.

This stance pushes back against the “low T for every tired man” culture. Many conservative patients will see that as long overdue. Medicine should not turn normal aging into a disease to sell therapies. But it also leaves a gray zone. Millions of men in their fifties and sixties have low testosterone, real symptoms, and no obvious single cause. Their doctors now have better safety data but still must prescribe off-label, balancing improved quality of life against blood-pressure and clotting concerns with no Food and Drug Administration blessing.

The safety picture is better, but not clean

TRAVERSE and follow-up summaries point to an important nuance: no extra major cardiovascular events does not mean no risk at all. Secondary analyses saw higher rates of atrial fibrillation, acute kidney injury, pulmonary embolism, and more fractures in the testosterone group. Other research and expert reviews highlight a slight rise in clot-related events like pulmonary embolism and caution against use in men with clotting disorders or past venous clots. Cardiologists now advise close monitoring rather than blind comfort.

📣 FIRST ON THE DAILY SIGNAL: The FDA just loosened its label on testosterone replacement therapy—clearing the way for the 20-25% of young men with testosterone deficiency to more easily access treatment.

An FDA panel found last December that TRT does not increase risk of…

— The Daily Signal (@DailySignal) June 18, 2026

At the same time, a large body of work links low testosterone itself to higher rates of cardiovascular disease, diabetes, depression, and even early death. Some researchers argue that properly monitored testosterone therapy may help men stay healthier and function better for longer, especially when combined with weight loss, exercise, and control of blood pressure and blood sugar. Trials show no increase in prostate cancer risk with therapy, and one large Medicare study even found lower prostate cancer rates among treated men.

What this really means for your decisions

If you are a middle-aged man weighing testosterone therapy, the new Food and Drug Administration move changes the question you should ask. The old question was, “Will this drug give me a heart attack?” The best current evidence says no, when used for true hypogonadism and monitored properly. The smarter question now is, “Can I afford a bump in blood pressure, and am I willing to be monitored and adjust my lifestyle and medications if needed?” That is a very different risk calculus.

For men who already take testosterone, the label update should feel like cautious vindication, not a green light to chase bodybuilder doses. You and your doctor should track blood pressure, watch for signs of clotting or atrial fibrillation, and keep an honest eye on sleep apnea, weight, and alcohol use. For men considering therapy mainly to fight normal aging, start with sleep, strength training, diet, and metabolic health before adding a hormone that will now carry a clear blood-pressure warning in bold print.